Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival

Lixia Xu ¹, Xiaoxing Li , Eagle S H Chu

⁰Institute of Digestive Disease and Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong.

Gut +

|

September 16, 2011

View abstract on PubMed

Summary

BCL6B promoter hypermethylation silences this tumor suppressor in gastric cancer, inhibiting cell growth and improving patient prognosis. Methylated BCL6B serves as a novel biomarker for gastric cancer.

Area Of Science

Oncology
Epigenetics
Molecular Biology

Background

Gastric cancer (GC) remains a significant global health challenge with complex underlying mechanisms.
Epigenetic alterations, particularly DNA methylation, play a crucial role in cancer development and progression.
BCL6B (B cell CLL/lymphoma 6 member B) has emerged as a gene of interest due to its potential role in various cancers.

Purpose Of The Study

To investigate the epigenetic regulation of BCL6B in gastric cancer.
To elucidate the biological functions of BCL6B in GC development.
To assess the clinical significance and prognostic value of BCL6B in patients with gastric cancer.

Main Methods

Genome-wide promoter methylation assays identified BCL6B as a methylated gene in cancer.
Combined bisulfite restriction analysis and sequencing evaluated BCL6B promoter methylation.
Cell viability, colony formation, flow cytometry, and in vivo tumorigenicity assays assessed BCL6B's biological functions.
cDNA expression arrays identified BCL6B's molecular targets.

Main Results

BCL6B was silenced or downregulated in GC cell lines due to promoter hypermethylation, contrasting with expression in normal gastric tissues.
Re-expression of BCL6B inhibited GC cell proliferation, colony formation, and tumorigenicity while inducing apoptosis.
BCL6B hypermethylation was prevalent in GC patient cohorts and independently correlated with poorer patient survival.

Conclusions

BCL6B functions as a tumor suppressor in gastric cancer, with its silencing mediated by promoter hypermethylation.
Methylated BCL6B represents a promising independent biomarker for predicting gastric cancer prognosis.

Related Concept Videos